More FDA Review And Decision Data
For first-in-class devices or major new device indications going through FDA, 2015 was a banner year.
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
FDA Hits User-Fee-Era Record For 'Novel' Devices: A New Normal?
Approvals of PMAs and panel-track supplements, as well as de novo devices, hit a 15-year high in calendar year 2015, according to a "Gray Sheet" analysis. FDA and industry experts respond to the data; also, check out our infographic of 2015 FDA approval trends, including a tally of the firms that captured the most PMAs and 510(k)s last year, and more.
More from Regulation
• By
Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.
• By
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
• By
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
• By
The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.
More from Policy & Regulation
• By
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
• By
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
• By
The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.